Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a report published on Tuesday morning. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Trading Down 2.6 %

NYSE:ENZ opened at $0.53 on Tuesday. Enzo Biochem has a 1 year low of $0.51 and a 1 year high of $1.40. The firm has a 50 day moving average of $0.73 and a 200-day moving average of $0.98.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings data on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.

Institutional Trading of Enzo Biochem

Several hedge funds have recently modified their holdings of ENZ. Virtu Financial LLC acquired a new stake in Enzo Biochem in the fourth quarter worth about $35,000. Lepercq Multi Asset Fund acquired a new position in Enzo Biochem during the 4th quarter valued at about $88,000. BBR Partners LLC bought a new position in shares of Enzo Biochem in the 3rd quarter valued at about $112,000. Finally, Geode Capital Management LLC grew its position in shares of Enzo Biochem by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after buying an additional 11,742 shares during the period. 36.90% of the stock is owned by institutional investors.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.